Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10021


Purpose:

The purpose of this study is to determine the effect of an adrenocorticoid antagonist (ketoconazole), 600 mg per day for 4 weeks, in the treatment of patients with central serous chorioretinopathy (CSC).


Study summary:

A complete ophthalmic evaluation and tests: autofluorescence and Fluorescein angiography, Color Fundus Photography, OCT, including liver and adrenal functions and pregnancy test, if applicable will be done on the screening visit. If the patient is eligible, the patient will be started on ketoconazole 600 mg per day by mouth for the following next 6 weeks. The patient will be rechecked at weeks 5-6, 10,14 and 18. During all these visits a complete ophthalmic examination autofluorescence, OCT, and color fundus photographs will be done. Repeat Liver and Adrenal function tests will be done at weeks 5-6 and 10 visits. On the exit visit, all the ophthalmic tests and procedures on the baseline visit will be done. Adverse events, and concomitant medications and treatments will be reported on all visits.


Criteria:

Inclusion Criteria: 1. Age less than 60 years 2. Must have clinical signs of CSC with leakage from the level of the RPE during fluorescein angiography and neurosensory detachment documented by optical coherence tomography (OCT). 3. Be able to return for all study visits for 3 months' duration. 4. Be able to provide written informed consent 5. Must have sufficiently clear media to allow for adequate fundus photography Exclusion Criteria: 1. Have choroidal neovascularization. 2. Have any evidence of clinically significant intraocular inflammation, angioid streaks, presumed ocular histoplasmosis syndrome, or other precursor of choroidal neovascularization. 3. Have additional eye disease that compromises the visual acuity of the study eye. 4. Are receiving any systemic steroid therapy 5. Have any significant medical history 6. Have a history of severe hypersensitivity reaction to any of the dyes or the drug used in the study. 7. Have any history of ocular conditions that may mimic CSC 8. Are pregnant


NCT ID:

NCT00211393


Primary Contact:

Principal Investigator
K. Bailey Freund, MD
Manhattan Eye, Ear & Throat Hospital


Backup Contact:

N/A


Location Contact:

New York, New York 10021
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.